Mitochondrial DNA determines the cellular response to cancer therapeutic agents

Related Experiment Video

Updated: Oct 18, 2026

Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

K K Singh1, J Russell, B Sigala

  • 1Johns Hopkins Oncology Center, Baltimore, MD 21287, USA.

Oncogene
|December 22, 1999
PubMed

Insights

Mitochondrial DNA (mitDNA) is crucial for cancer drug response. Cells lacking mitDNA show resistance to adriamycin and photodynamic therapy, indicating mitDNA

Area of Science:

  • Cancer Biology
  • Mitochondrial Biology
  • Pharmacology

Background:

  • Mitochondrial dysfunction and mutations in mitochondrial DNA (mitDNA) are observed in various cancers.
  • The role of mitDNA-encoded functions in cancer therapeutic response remains largely unknown.

Purpose of the Study:

  • To investigate the significance of mitDNA-encoded functions in cellular sensitivity to anticancer agents.
  • To determine if mitDNA integrity influences the efficacy of chemotherapy and other cancer therapies.

Main Methods:

  • Comparison of clonogenic survival between a human cervical cancer cell line (HeLa, Rho+) and its mitDNA-depleted derivative (Rho0) after exposure to various anticancer agents.
  • Assessment of adriamycin uptake, apoptotic cell death, and cell cycle response in Rho+ and Rho0 cells.
  • Analysis of mitDNA mutations following adriamycin treatment.

Main Results:

  • Rho0 cells lacking mitDNA exhibited extreme resistance to adriamycin and photodynamic therapy (PDT).
  • No significant difference in response was observed between Rho+ and Rho0 cells when treated with alkylating agents or gamma radiation.
  • Adriamycin resistance in Rho0 cells was not attributed to altered apoptosis, cell cycle, or drug uptake.
  • Adriamycin treatment induced mutations in the mitDNA of HeLa cells.

Conclusions:

  • Mitochondrial DNA plays a critical role in cellular sensitivity to specific cancer therapeutic agents like adriamycin and PDT.
  • Targeting or preserving mitDNA function could be a strategy to modulate cancer treatment efficacy.

More Related Videos

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates11:32

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates

Published on: August 6, 2021

Related Concept Videos

Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...